Abstract
Cardiac involvement in systemic amyloidosis carries poor prognosis with a median survival of 5 months.(1) The authors report an unusual presentation of cardiac amyloidosis in the form of predominant mitral regurgitation. The patient responded very well to medical therapy with subsequent improvement of mitral valve dysfunction. The authors would like to highlight this multisystem involvement and the presence of a complex overlap of systemic features.
MeSH terms
-
Adult
-
Amyloid / analysis
-
Amyloid / metabolism*
-
Amyloidosis / diagnosis*
-
Amyloidosis / drug therapy
-
Biopsy, Needle
-
Blood Chemical Analysis
-
Blood Pressure Determination / methods
-
Cyclophosphamide / administration & dosage
-
Dexamethasone / administration & dosage
-
Diagnosis, Differential
-
Drug Therapy, Combination
-
Dyspnea / diagnosis
-
Dyspnea / etiology
-
Echocardiography / methods
-
Electrocardiography / methods
-
Follow-Up Studies
-
Humans
-
Immunohistochemistry
-
Male
-
Mitral Valve Insufficiency / diagnosis*
-
Mitral Valve Insufficiency / therapy
-
Treatment Outcome
Substances
-
Amyloid
-
Dexamethasone
-
Cyclophosphamide